Martin Tolar, Founder and CEO of Alzheon, discusses the crucial role patient stratification and diagnostics will have to play in the development of disease-modifying drugs for AD.
Jason Christiansen, Vice President, Diagnostics at Ignyta discuss the best way to co-develop drug and diagnostic and how to deliver the value of diagnostic testing to patients.
This white paper has been developed in collaboration with ANGLE plc.
Liquid biopsy: Cells for Precision Medicine
J. Carl Barrett, VP, Translational Sciences Oncology, AstraZeneca
The results from the 2015 Companion Diagnostics Industry Survey
View the full report from the 2016 Companion Diagnostics Industry Survey
See what Mark Roberts from Covance has to say on perspectives on drug-companion diagnostic co-development.
See what Klaus Lindpaintner from Thermo Fisher Scientific has to say on perspectives on drug-companion diagnostic co-development.
See what Marielena Mata from GSK has to say on perspectives on drug-companion diagnostic co-development.
Eric Rubin, MD, Vice President & Therapeutic Area Head Oncology Early Development at Merck Research Laboratories recently spoke about some of the key challenges and opportunities with drug-companion diagnostic development in the run up to World CDx Boston 2016, October 18-21.
See why Gavin MacBeath, Co-Founder and Senior Vice President Merrimack Pharmaceuticals thinks CDX is so critical to biomarker based drug development